324 related articles for article (PubMed ID: 33091440)
1. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
Wang QQ; Hua HY; Naranmandura H; Zhu HH
Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
[TBL] [Abstract][Full Text] [Related]
2. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H
Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488
[TBL] [Abstract][Full Text] [Related]
3. Pyrrolidine Dithiocarbamate Enhances the Cytotoxic Effect of Arsenic Trioxide on Acute Promyelocytic Leukemia Cells.
Yu S; Ge Z; Chen W; Han J
Comb Chem High Throughput Screen; 2023; 26(11):2067-2076. PubMed ID: 36694317
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias.
Yousefnia S
Cell Biol Int; 2021 Jun; 45(6):1148-1157. PubMed ID: 33527587
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
6. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
Chou WC; Dang CV
Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases.
Wang QQ; Jiang Y; Naranmandura H
Metallomics; 2020 Mar; 12(3):326-336. PubMed ID: 32163072
[TBL] [Abstract][Full Text] [Related]
8. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
[TBL] [Abstract][Full Text] [Related]
9. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
[TBL] [Abstract][Full Text] [Related]
10. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide: mechanisms of action.
Davison K; Mann KK; Miller WH
Semin Hematol; 2002 Apr; 39(2 Suppl 1):3-7. PubMed ID: 12012315
[TBL] [Abstract][Full Text] [Related]
12. Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide.
Bankar A; Korula A; Kulkarni UP; Devasia AJ; Na F; Lionel S; Abraham A; Balasubramanian P; Janet NB; Nair SC; S S; Jeyaseelan V; N J; Prasad J; George B; Mathews V
Br J Haematol; 2020 Apr; 189(2):269-278. PubMed ID: 31863602
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
[TBL] [Abstract][Full Text] [Related]
14. c-Myc Inhibition Using 10058-F4 Increased the Sensitivity of Acute Promyelocytic Leukemia Cells to Arsenic Trioxide Via Blunting PI3K/NF-κB Axis.
Sayyadi M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Abolghasemi H; Anoushirvani AA; Bashash D
Arch Med Res; 2020 Oct; 51(7):636-644. PubMed ID: 32553459
[TBL] [Abstract][Full Text] [Related]
15. Arsenic induced epigenetic changes and relevance to treatment of acute promyelocytic leukemia and beyond.
Maimaitiyiming Y; Wang QQ; Hsu CH; Naranmandura H
Toxicol Appl Pharmacol; 2020 Nov; 406():115212. PubMed ID: 32882258
[TBL] [Abstract][Full Text] [Related]
16. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
[TBL] [Abstract][Full Text] [Related]
17. Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide.
Cao F; Li X; Yang Y; Fang H; Qu H; Chang N; Ma Q; Cao W; Zhou J; Wang W
OMICS; 2019 Feb; 23(2):119-130. PubMed ID: 30767729
[TBL] [Abstract][Full Text] [Related]
18. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
19. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
20. Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
Guo S; Wang X; Gao C; Wu Z; Chen H; Lin L; Guo M; Gao Y; Hai X
Toxicol Lett; 2021 Sep; 347():78-85. PubMed ID: 33865921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]